Cargando…

Intraocular pressure effect of intravitreal conbercept injection for retinopathy of prematurity

Purpose: Intravitreal injection of conbercept (IVC) is a novel anti-vascular endothelial growth factor (anti-VEGF) treatment for retinopathy of prematurity (ROP). This study aimed to assess the intraocular pressure (IOP) effect of IVC. Methods: All IVC surgeries were performed in the Department of O...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Caifeng, Mu, Ge, Zhao, Huanhuan, Zheng, Jiao, Feng, Qingyang, Wu, Yining, Li, Yinan, Huang, Xuelin, Sun, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10266213/
https://www.ncbi.nlm.nih.gov/pubmed/37324456
http://dx.doi.org/10.3389/fphar.2023.1165356
_version_ 1785058700252151808
author Gao, Caifeng
Mu, Ge
Zhao, Huanhuan
Zheng, Jiao
Feng, Qingyang
Wu, Yining
Li, Yinan
Huang, Xuelin
Sun, Wei
author_facet Gao, Caifeng
Mu, Ge
Zhao, Huanhuan
Zheng, Jiao
Feng, Qingyang
Wu, Yining
Li, Yinan
Huang, Xuelin
Sun, Wei
author_sort Gao, Caifeng
collection PubMed
description Purpose: Intravitreal injection of conbercept (IVC) is a novel anti-vascular endothelial growth factor (anti-VEGF) treatment for retinopathy of prematurity (ROP). This study aimed to assess the intraocular pressure (IOP) effect of IVC. Methods: All IVC surgeries were performed in the Department of Ophthalmology, Guangdong Women and Children Hospital, from January 2021 to May 2021. In this study, 30 eyes of 15 infants who received intravitreal injections of conbercept at a dose of 0.25 mg/0.025 mL were included. The IOP of all participants was measured prior to administering the injection and subsequently at 2 min, 1 h, 1 day, and 1 week thereafter. Results: We included 30 eyes (10 boys and 5 girls) with ROP. For the male group, the mean birth weight, mean gestational age at birth, and the mean time of postmenstrual age (PMA) at IVC treatment were 1,174.0 ± 446.0 g, 28.4 ± 3.0 weeks, and 37.1 ± 1.6 weeks, respectively; for the female group, they were 1,108 ± 285.5 g, 28.2 ± 2.5 weeks, and 36.8 ± 2.1 weeks, respectively. For the male group, the IOP at baseline, 2 min, 1 h, 1 day, and 1 week after IVC were 12.4 ± 1.5 mmHg, 49.0 ± 3.1 mmHg, 26.3 ± 2.5 mmHg, 13.4 ± 2.2 mmHg, and 11.6 ± 1.7 mmHg, respectively; for the female group, they were 10.7 ± 2.0 mmHg, 47.3 ± 3.2 mmHg, 26.4 ± 3.2 mmHg, 10.7 ± 1.8 mmHg, and 10.2 ± 1.8 mmHg, respectively. In both groups, the IOP immediately (2 min) after the operation was significantly higher than that at any other time point (p < 0.01). IOP values returned to the preoperative baseline level on the first day after surgery, with no significant difference compared with that before injection (p > 0.05). IOP continued to be maintained at the preoperative baseline level on the first week after surgery, with no significant difference compared with that before surgery (p > 0.05). Conclusion: Infants with ROP who received IVC experienced a sharp increase in the IOP immediately after injection, which decreased to below 30 mmHg after 1 h and maintain that level for 1 week or longer.
format Online
Article
Text
id pubmed-10266213
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-102662132023-06-15 Intraocular pressure effect of intravitreal conbercept injection for retinopathy of prematurity Gao, Caifeng Mu, Ge Zhao, Huanhuan Zheng, Jiao Feng, Qingyang Wu, Yining Li, Yinan Huang, Xuelin Sun, Wei Front Pharmacol Pharmacology Purpose: Intravitreal injection of conbercept (IVC) is a novel anti-vascular endothelial growth factor (anti-VEGF) treatment for retinopathy of prematurity (ROP). This study aimed to assess the intraocular pressure (IOP) effect of IVC. Methods: All IVC surgeries were performed in the Department of Ophthalmology, Guangdong Women and Children Hospital, from January 2021 to May 2021. In this study, 30 eyes of 15 infants who received intravitreal injections of conbercept at a dose of 0.25 mg/0.025 mL were included. The IOP of all participants was measured prior to administering the injection and subsequently at 2 min, 1 h, 1 day, and 1 week thereafter. Results: We included 30 eyes (10 boys and 5 girls) with ROP. For the male group, the mean birth weight, mean gestational age at birth, and the mean time of postmenstrual age (PMA) at IVC treatment were 1,174.0 ± 446.0 g, 28.4 ± 3.0 weeks, and 37.1 ± 1.6 weeks, respectively; for the female group, they were 1,108 ± 285.5 g, 28.2 ± 2.5 weeks, and 36.8 ± 2.1 weeks, respectively. For the male group, the IOP at baseline, 2 min, 1 h, 1 day, and 1 week after IVC were 12.4 ± 1.5 mmHg, 49.0 ± 3.1 mmHg, 26.3 ± 2.5 mmHg, 13.4 ± 2.2 mmHg, and 11.6 ± 1.7 mmHg, respectively; for the female group, they were 10.7 ± 2.0 mmHg, 47.3 ± 3.2 mmHg, 26.4 ± 3.2 mmHg, 10.7 ± 1.8 mmHg, and 10.2 ± 1.8 mmHg, respectively. In both groups, the IOP immediately (2 min) after the operation was significantly higher than that at any other time point (p < 0.01). IOP values returned to the preoperative baseline level on the first day after surgery, with no significant difference compared with that before injection (p > 0.05). IOP continued to be maintained at the preoperative baseline level on the first week after surgery, with no significant difference compared with that before surgery (p > 0.05). Conclusion: Infants with ROP who received IVC experienced a sharp increase in the IOP immediately after injection, which decreased to below 30 mmHg after 1 h and maintain that level for 1 week or longer. Frontiers Media S.A. 2023-05-30 /pmc/articles/PMC10266213/ /pubmed/37324456 http://dx.doi.org/10.3389/fphar.2023.1165356 Text en Copyright © 2023 Gao, Mu, Zhao, Zheng, Feng, Wu, Li, Huang and Sun. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Gao, Caifeng
Mu, Ge
Zhao, Huanhuan
Zheng, Jiao
Feng, Qingyang
Wu, Yining
Li, Yinan
Huang, Xuelin
Sun, Wei
Intraocular pressure effect of intravitreal conbercept injection for retinopathy of prematurity
title Intraocular pressure effect of intravitreal conbercept injection for retinopathy of prematurity
title_full Intraocular pressure effect of intravitreal conbercept injection for retinopathy of prematurity
title_fullStr Intraocular pressure effect of intravitreal conbercept injection for retinopathy of prematurity
title_full_unstemmed Intraocular pressure effect of intravitreal conbercept injection for retinopathy of prematurity
title_short Intraocular pressure effect of intravitreal conbercept injection for retinopathy of prematurity
title_sort intraocular pressure effect of intravitreal conbercept injection for retinopathy of prematurity
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10266213/
https://www.ncbi.nlm.nih.gov/pubmed/37324456
http://dx.doi.org/10.3389/fphar.2023.1165356
work_keys_str_mv AT gaocaifeng intraocularpressureeffectofintravitrealconberceptinjectionforretinopathyofprematurity
AT muge intraocularpressureeffectofintravitrealconberceptinjectionforretinopathyofprematurity
AT zhaohuanhuan intraocularpressureeffectofintravitrealconberceptinjectionforretinopathyofprematurity
AT zhengjiao intraocularpressureeffectofintravitrealconberceptinjectionforretinopathyofprematurity
AT fengqingyang intraocularpressureeffectofintravitrealconberceptinjectionforretinopathyofprematurity
AT wuyining intraocularpressureeffectofintravitrealconberceptinjectionforretinopathyofprematurity
AT liyinan intraocularpressureeffectofintravitrealconberceptinjectionforretinopathyofprematurity
AT huangxuelin intraocularpressureeffectofintravitrealconberceptinjectionforretinopathyofprematurity
AT sunwei intraocularpressureeffectofintravitrealconberceptinjectionforretinopathyofprematurity